DuPont Offers New Probiotic Solution for Immunity
A successful human clinical trial was carried out in Australia to see if the positive results obtained on children also could be observed in adults.
31 Aug 2012 --- HOWARU Protect, part of the DuPont Danisco range of premium probiotics, is expanding its target population with new proven positive results on adults.
A successful human clinical trial was carried out in Australia to see if the positive results obtained on children also could be observed in adults.
HOWARU Protect has shown in adults
• A significant reduction in the number of days experiencing common cold- and flu-associated symptoms
• A strong trend in the reduction of cold and flu medication use
• A trend toward the reduction rate of chest illness symptom episodes
The study recruited 263 randomized healthy physically active adults who received either HOWARU Protect or a placebo for 150 days. The health status and the level of physical activity of the volunteers were monitored over the course of the study.
The study was conducted by the Australian Institute of Sport and by Griffith University, Australia. The positive results of this new study in healthy adults support and build on the previously published outstanding results on children.*
Results on this new HOWARU Protect study on adults will be presented during Vitafoods Asia in Hong-Kong by Anneli Tarpila, Ph. D., Clinical Trial Manager, DuPont Nutrition & Health.
Tarpila will share the latest insights with a presentation entitled "PROTECT yourself from colds and flu with good bacteria.” The seminar will be held on 6 September at 2:00 pm in the Seminar Theatre.
* G.Leyer; S.Li et al. Probiotic Effects on Cold and Influenza-Like Symptom Incidence and Duration in Children; Pediatrics August 2009; 124:2 e172-e179
